

Entest BioMedical Inc.'s Zander Therapeutics Unit: Initial Focus is Small Molecule and Cancer Stem Targeting for Veterinary Oncology

Zander Oncology Platform includes immunotherapy, small molecule, gene silencing and cancer stem cell targeting for Canine Cancer and Feline Leukemia

03 Aug, 2015, 16:00 ET from Entest BioMedical Inc.

SAN DIEGO, August 3, 2015 /PRNewswire/ -- Zander Therapeutics, a wholly owned subsidiary of Entest BioMedical Inc. (OTC: ENTBD), announced today its canine cancer therapeutics and feline leukemia platforms. These platforms will focus on adopting cutting edge technologies such as immune-oncology, small molecule, gene silencing and cancer stem cell targeting for the treatment of cancer in dogs and leukemia in cats.

Zander has focused its attention on the highly profitable veterinary market. It has been estimated that the U.S. market for veterinary care is over \$15 billion per year (see http://www.americanpetproducts.org/press_industrytrends.asp).

The Company believes the veterinary drug market is substantially lagging the human drug market. The Company feels that this serves as unique niche opportunity. Despite the striking similarity of the genome between dogs and humans, there is a dearth of rational drug discovery and translation of human targeted therapeutics to the veterinary market. Targeted therapy is an approach that uses molecular biology to identify the specific genes that cause cancer, this leads to the process of rational drug discovery, which is the development of drugs designed to correct the specific genetic mutations found in cancer.

Entest's Zander unit recently licensed IP from Regen BioPharma Inc. (OTCBB: RGBP and PINK: RGBP) that will allow the Company to develop both novel, first-in-class, "smart" drugs for veterinary therapies as well as immune-oncology drugs. Zander will also strive to identify co-development opportunities which would lead to fast tracking drug development.

One in every three dogs will develop cancer during its lifetime. Sadly, such cancers kill nearly half of all pet dogs over the age of ten; animals that are family to millions of pet owners. Pet owners are willing to pay the cost for the necessary treatments meant to save the lives of their loved ones. With the ASPCA citing approximately 78 million dogs as pets within the United States, the veterinary care market represents enormous revenue potential.

About Entest BioMedical Inc.:

Entest BioMedical Inc. (OTC PINK: ENTBD) is a developer of veterinary medicines that harness the animal's own reparative / immunological mechanisms. The Company, through its Zander Therapeutics unit, is also pursuing cancer therapeutics for veterinary application. Zander Therapeutics Inc. is developing small molecule and cancer stem cell therapies for treating Feline Leukemia and Canine Cancer. Zander is a wholly owned subsidiary of Entest BioMedical Inc.

Disclaimer

This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.

Contact:

David R. Koos

Chairman & CEO

Entest BioMedical Inc.

+1-619-702-1404 phone

+1-619-330-2328 fax

SOURCE Entest BioMedical Inc.